Acorda's MS Drug Amaya Panel Review Leaves Little Time To React
This article was originally published in The Pink Sheet Daily
Executive Summary
The Peripheral and Central Nervous System Drugs Advisory Committee will review the mobility-enhancing drug one week before its scheduled PDUFA date.